AMGN · NASDAQ
Amgen Inc.
$439.26 -8.19 (-1.83%)
Company overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due to a low white blood cell count in patients with cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronar…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Market cap
- $237B
- Employees
- 28,000
- Headquarters
- Thousand Oaks, CA
- Website
- amgen.com
- CEO
- Robert A. Bradway
- Listed
- June 17, 1983
- P/E
- 30.34
- Dividend yield
- 2.26%
Company financials
- Revenue
- $37.2B
- Gross profit
- $26.6B
- Operating income
- $11.8B
- EBITDA
- $17.3B
- Net income
- $7.8B
- EPS
- $14.48
- Total assets
- $92.5B
- Total debt
- $57.3B
- Gross margin
- 71.46%
- Net margin
- 20.95%
- Earnings yield
- 3.30%
Showing FY 2025
AMGN
1D
NASDAQ
O441.55H450.98L437.19C447.28+8.94 (+2.04%)Vol3.11M